Showing results (181-190 of 280) with videos related to

Sort By:
Pageof 28
Leukemia|March 30, 2019
Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapyAreej El-Jawahri, Gregory A Abel, Lara Traeger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2022
Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction CorrelatesEvan C Chen, Helen Gandler, Isidora Tošić, et al.
Leukemia Research|July 25, 2025
Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control studyAndreas Reiter, Jason Gotlib, Iván Álvarez-Twose, et al.
Leukemia|February 20, 2024
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AMLShai Shimony, Jan Philipp Bewersdorf, Rory M Shallis, et al.
Nature Medicine|December 7, 2021
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trialDaniel J DeAngelo, Deepti H Radia, Tracy I George, et al.
Cancer|January 19, 2023
Psychological mobile app for patients with acute myeloid leukemia: A pilot randomized clinical trialAreej El-Jawahri, Marlise R Luskin, Joseph A Greer, et al.
Leukemia|July 5, 2022
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosisAndreas Reiter, Jason Gotlib, Iván Álvarez-Twose, et al.
Blood|January 1, 2015
Acute myeloid leukemia ontogeny is defined by distinct somatic mutationsR Coleman Lindsley, Brenton G Mar, Emanuele Mazzola, et al.
The Lancet. Oncology|February 29, 2024
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 studyNaval G Daver, Pau Montesinos, Daniel J DeAngelo, et al.
Nature Medicine|February 14, 2017
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemiaNina Fenouille, Christopher F Bassil, Issam Ben-Sahra, et al.
Pageof 28